Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 7/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.48 |
| ▸ | GABRP | O00591 | 6/20 | 0.48 |
| ▸ | GABRD | O14764 | 6/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.48 |
| ▸ | GABRE | P78334 | 6/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28532069 | 0.85 | ALDH1A1 (0.54) | CYP1A2GABRA2GABRB2NPC1MAPT | |
| SCHEMBL27686080 | 0.85 | MAPT (0.49) | CYP1A2GABRA2GABRB2GABRA1GABRG2 | |
| SCHEMBL19717403 | 0.83 | MAPT (0.46) | CYP1A2GABRA2GABRB2NPC1MAPT | |
| SCHEMBL31172628 | 0.82 | CYP1A2 (0.55) | CYP1A2GABRA2GABRB2GABRA1GABRG2 | |
| SCHEMBL82426 | 0.82 | CYP1A2 (0.55) | CYP1A2GABRA2GABRB2GABRA1GABRG2 | |
| SCHEMBL28545895 | 0.81 | MAPT (0.46) | CYP1A2GABRA2GABRB2GABRA1GABRG2 | |
| SCHEMBL23013933 | 0.81 | CXCR1 (0.43) | CYP1A2NPC1MAPTKDM4EALDH1A1 | |
| SCHEMBL29703835 | 0.81 | CXCR1 (0.43) | CYP1A2NPC1MAPTKDM4EALDH1A1 | |
| SCHEMBL10003611 | 0.81 | CYP1A2 (0.53) | CYP1A2GABRA2GABRB2GABRA1GABRG2 | |
| SCHEMBL229176 | 0.81 | CA12 (0.55) | CYP1A2GABRA2GABRB2GABRA1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12522600-B2 | Crystal form and salt form of bromine domain protein inhibitor and preparation method therefor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-01-13 | — | — | US | disclosed |
| CN-114929703-B | Crystal form and salt form of bromodomain protein inhibitor and preparation method thereof | 正大天晴药业集团股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-07-09 | — | — | US | disclosed |
| CN-112204009-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20240101551-A1 | CRYSTAL FORM AND SALT FORM OF BROMINE DOMAIN PROTEIN INHIBITOR AND PREPARATION METHOD THEREFOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-3452456-B1 | BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-7074809-B2 | Compounds | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| EP-1581525-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | AstraZeneca AB (SE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1562595-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY | 2004-06-03 | — | — | US | disclosed |
| US-20040106607-A1 | New compounds | ASTRAZENECA AB AND NPS PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004026305-A9 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | LILLY CO ELI (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004026305-A1 | DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
| EP-1397364-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2004-03-17 | — | — | EP | disclosed |
| WO-2004014902-A2 | COMPOUNDS HAVING AN ACTIVITY AT METABOTROPIC GLUTAMATE RECEPTORS | ASTRAZENECA AB (SE) | 2004-02-19 | — | — | WO | disclosed |
| WO-2002094833-A1 | NOVEL PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | ELI LILLY AND COMPANY (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030880-B2 | Iminosulfanone compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof | BRD4, BRD1, BRD3 | CYP1A2 2636/4885GABRA2 2778/4885GABRB2 2532/4885 |
| US-20240101551-A1 | CRYSTAL FORM AND SALT FORM OF BROMINE DOMAIN PROTEIN INHIBITOR AND PREPARATION METHOD THEREFOR | BET1, BRD7, BRWD1 | CYP1A2 4732/4885GABRA2 2558/4885GABRB2 2249/4885 |
| US-20040106607-A1 | New compounds | MTX1, MLX, TPX2 | CYP1A2 274/4885GABRA2 3646/4885GABRB2 3449/4885 |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | CYP1A2 2965/4885GABRA2 2994/4885GABRB2 1509/4885 |
| US-20040106604-A1 | Novel pyrrole derivatives as pharmaceutical agents | TGFBR1, SMAD3, TGFBR2 | CYP1A2 3968/4885GABRA2 1100/4885GABRB2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.